Timothy G. Call
YOU?
Author Swipe
View article: Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
Supplementary Figure Legends
View article: Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
Supplementary Table S1
View article: Non-CLL-type MBL and chip are associated precursor conditions: Insights from Mayo Clinic's MBL screening cohort
Non-CLL-type MBL and chip are associated precursor conditions: Insights from Mayo Clinic's MBL screening cohort Open
Background: Monoclonal B-cell lymphocytosis (MBL), a precursor to chronic lymphocytic leukemia (CLL), is an understudied yet common premalignant condition present in ~8 million adults in the United States. Based on flow cytometry, MBL can …
View article: The role of imaging studies in predicting time to first treatment and overall survival in high‐count monoclonal B‐cell lymphocytosis
The role of imaging studies in predicting time to first treatment and overall survival in high‐count monoclonal B‐cell lymphocytosis Open
Summary In individuals with high‐count monoclonal B‐cell lymphocytosis (MBL), we investigated if lymphadenopathy or splenomegaly found by imaging was associated with shorter time to first chronic lymphocytic leukaemia (CLL) therapy (TTFT) …
View article: Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells Open
Supplementary Figure Legends
View article: Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells Open
Supplementary Table S2
View article: Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells Open
Supplementary Table S1
View article: Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells Open
Supplementary Figure Legends
View article: Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells Open
Supplementary Table S2
View article: Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells Open
Supplementary Figures S1-S17
View article: Data from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Data from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells Open
The receptor tyrosine kinase AXL is a member of the TAM (Tyro3, AXL, and proto-oncogene tyrosine-protein kinase Mer) family and plays pleiotropic roles in cancer progression. AXL is expressed in immunosuppressive cells, which contributes t…
View article: Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells Open
Supplementary Table S1
View article: Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells Open
Supplementary Figures S1-S17
View article: Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms Open
View article: Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia
Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia Open
View article: Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis
Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis Open
High-count monoclonal B-cell lymphocytosis (HCMBL) is a precursor condition to chronic lymphocytic leukemia (CLL). We have shown that among individuals with HCMBL, the CLL-International Prognostic Index (CLL-IPI) is prognostic for time-to-…
View article: Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
Supplementary Table S1
View article: Data from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Data from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
The receptor tyrosine kinase AXL is a member of the TYRO3, AXL, and proto-oncogene tyrosine-protein kinase MER family and plays pleiotropic roles in cancer progression. AXL is expressed in immunosuppressive cells, which contributes to decr…
View article: Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
Supplementary Table S2
View article: Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
Supplementary Figure Legends
View article: Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
Supplementary Figure Legends
View article: Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
Supplementary Table S1
View article: Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
Supplementary Table S2
View article: Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
Supplementary Figures S1-S17
View article: Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
Supplementary Figures S1-S17
View article: Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatment
Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatment Open
Patients with chronic lymphocytic leukemia (CLL) are at increased risk of developing non-hematologic malignancies.1 Definitive or adjuvant radiation therapy is often a critical component of management for localized solid organ cancers. Wit…
View article: Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
Supplementary Figures S1-S17
View article: Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
Supplementary Figure Legends
View article: Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
Supplementary Table S2
View article: Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells Open
Supplementary Table S2